Abstract
Reliable, short-term forecasts of traditional public health reporting streams (such as cases, hospitalizations, and deaths) are a key ingredient in effective public health decision-making during a pandemic. Since April 2020, our research group has worked with data partners to collect, curate, and make publicly available numerous real-time COVID-19 indicators, providing multiple views of pandemic activity. This paper studies the utility of these indicators from a forecasting perspective. We focus on five indicators, derived from medical insurance claims data, web search queries, and online survey responses. For each indicator, we ask whether its inclusion in a simple model leads to improved predictive accuracy relative to a similar model excluding it. We consider both probabilistic forecasting of confirmed COVID-19 case rates and binary prediction of case “hotspots”. Since the values of indicators (and case rates) are commonly revised over time, we take special care to ensure that the data provided to a forecaster is the version that would have been available at the time the forecast was made. Our analysis shows that consistent but modest gains in predictive accuracy are obtained by using these indicators, and furthermore, these gains are related to periods in which the auxiliary indicators behave as “leading indicators” of case rates.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This material is based on work supported by gifts from Facebook, Google.org, the McCune Foundation, and Optum; Centers for Disease Control and Prevention (CDC) grant U01IP001121; the Canadian Statistical Sciences Institute; National Sciences and Engineering Research Council of Canada (NSERC) grant RGPIN-2021-02618; and National Science Foundation Graduate Research Fellowship Program (NSF GRFP) award DGE1745016.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
no IRB approval is required.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data is publicly available from the linked URL to the COVIDcast Epidata API.
https://cmu-delphi.github.io/delphi-epidata/api/covidcast.html
